Dr.Swapnila Roy
Abstract
Over the past decade, there has been a growing interest in the use of artificial intelligence (AI)
technology for analysing and interpreting biological or genetic data, accelerating drug discovery,
and identifying selective small-molecule modulators or rare molecules in addition to predicting their
behaviour. The use of artificial neural networks (ANNs) for the rapid analysis of massive amounts of
data, the development of novel hypotheses and treatment plans, the prediction of disease progression,
and the assessment of the pharmacological profiles of drug candidates may significantly enhance
treatment outcomes.By gathering in the particular cancer areas, diagnostic tests utilizing
nanoparticles (NPs) allow biomarker identification and guarantee precise medication delivery
planning. AI and NPs for cancer targeting may be used to create sophisticated algorithms that better
categorise different cancers and comprehend complicated disease patterns. This is so that treatment
outcomes may be improved. AI offers enormous possibilities for automation, quicker patient
interpretation of complicated illness information, and faster processing of complex medical data.
Nano medicine and nano transport systems are rapidly developing technological know-how, in which
materials in small range are subjected to function method of diagnostic gear or to supply healing
agents to precise focused web sites in a controlled manner. Nanotechnology presents one-of-a-kind
blessings in treating chronic human sicknesses by website-precise and goal-oriented delivery of
specific medicines. There are numerous applications of nano medicine (chemotherapeutic retailers,
organic agents, immunotherapeutic agents etc.) in the treatment of numerous illnesses. This review
emphasizes how AI may assist in logically converting clinical data into useful insights for cancer
treatment advanced drug delivery systems in different diseases and approval process for drug devices
in India, EU and USA.
Keywords: Artificial intelligence (AI), cancer, rheumatoid arthritis, diabetes, nanoparticles, drug devices’ approval process eumatoid
[This article belongs to International Journal of Advance in Molecular Engineering(ijame)]
Browse Figures
References
Kumar A, Sharipov M, Turaev A, Azizov S, Azizov I, Makhado E, et al. Polymer-Based hybrid nanoarchitectures for cancer therapy applications. Polymers (Basel). (2022) 14(15):3027. doi: 10.3390/polym14153027
Qindeel M, Sargazi S, Hosseinikhah SM, Rahdar A, Barani M, Thakur VK, et al. Porphyrin-based nanostructures for cancer theranostics: chemistry: fundamentals and recent advances. Chemistry Select. (2021) 6(48):14082–99. doi: 10.1002/slct.202103418.
Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-Based drug delivery system: a patient-friendly chemotherapy for oncology. Dose Response. (2020) 18(3):1559325820936161. doi: 10.1177/1559325820936161
Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J, Shainsky‐Roitman J, Lammers T, Schroeder A. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Advanced Materials. 2020 Apr;32(13):1901989.
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21. PMID: 33099022; PMCID: PMC7577280.
Veselov VV, Nosyrev AE, Jicsinszky L, Alyautdin RN, Cravotto G. Targeted delivery methods for anticancer drugs. Cancers (Basel). (2022) 14(3):622. doi: 10.3390/cancers14030622.
Liu X, Jiang J, Meng H. Transcytosis – an effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery. Theranostics. (2019) 9(26):8018–25. doi: 7150/thno.38587
Alomrani A., Badran M., Harisa G. I., ALshehry M., Alshamsan A., Alkholief M., et al. The Use of Chitosan-Coated Flexible Liposomes as a Remarkable Carrier to Enhance the Antitumor Efficacy of 5-fluorouracil against Colorectal Cancer. Saudi Pharm. J.2019, 27, 603–611.
Aydın B., Uçar E., Tekin V., İçhedef Ç., Teksöz S. Biocompatible Delivery System for Metformin: Characterization, Radiolabeling and In Vitro Anticancer Agents Med. Chem. 2020,20, 1626–1634.
Bai J., Duan J., Liu R., Du Y., Luo Q., Cui Y., et al. Engineered Targeting tLyp-1 Exosomes as Gene Therapy Vectors for Efficient Delivery of siRNA into Lung Cancer Cells. Asian J. Pharm. Sci.2020, 15, 461–471.
Das KP and J C (2023) Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. Front. Med. Technol. 4:1067144. doi: 10.3389/fmedt.2022.1067144
Zohuri B. Artificial intelligence integration with nanotechnology. JBGSR. (2020) 6(3). Availableat: https://biogenericpublishers.com/jbgsr.ms.id.00147.text/ (cited September 23, 2022). doi:46718/JBGSR.2020.06.000147
Priyom Bose. Optimizing Drug Delivery Using AI [Internet]. News-Medical.net. (2022) [cited 2022 Oct 5]. Available from: https://www.azolifesciences.com/article/Optimizing-Drug-Delivery-Using-AI.aspx.
Midtvedt B, Olsén E, Eklund F, Höök F, Adiels CB, Volpe G, et al. Fast and accurate nanoparticle characterization using deep-learning-enhanced off-axis holography. ACS Nano. (2021) 15(2):2240–50. doi: 10.1021/acsnano.0c06902
Li J, Dekanovsky L, Khezri B, Wu B, Zhou H, Sofer Z. Biohybrid micro- and nanorobots for intelligent drug delivery. Cyborg Bionic Systems. (2022) 2022:13. Article ID: 9824057. doi:34133/2022/9824057
| Volume | 01 |
| Issue | 01 |
| Received | November 26, 2023 |
| Accepted | December 12, 2023 |
| Published | January 6, 2024 |